Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome
A phase 1/2 trial of Azacitidine, Venetoclax and Obinutuzumab in acute myeloid leukaemia, run by Molecular Partners AG, active and no longer recruiting.
Overview
Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome is a phase 1/2 interventional study registered as NCT05673057 by Molecular Partners AG, with 249 participants enrolled, started 2022-12-29 and due to reach its primary completion in 2026-05-29. Interventions recorded: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1, MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm A, MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclax, MP0533 with Obinutuzumab pretreatment, MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B relapsed/refractory AML and MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B in treatment naïve patients.
Similar pages
not linked directly; found by shared links- TrialA Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TrialA Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TrialIMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TrialA Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TrialA Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TrialStudy to Evaluate the Safety and Tolerability of EP0042
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TrialA Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TrialStudy to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Shares Obinutuzumab, Venetoclax and the tag pipeline.